Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
暂无分享，去创建一个
J. Sparano | J. Wright | P. Christos | K. O’Brien | D. Hershman | L. Vahdat | S. Hoschander | T. Li | Paul J. Christos | Linda T. Vahdat | John J. Wright | D. Hershman | Tianhong Li | Katie M. O'Brien | John J Wright